“Romania is becoming a hub to us that supplies pharmaceuticals to the Baltic countries, Western Europe, Ukraine and Russia, but we want to expand to other parts of the world,” Sawhney told ZF in an interview.
Terapia Ranbaxy used to serve five or six countries other than Romania until a few years ago, and is now serving thirty. It will expand to become a global and more important player in Ranbaxy’s scheme, he added.
Ranbaxy, India’s largest pharmaceutical producer, bought Terapia Cluj in a record $324 million deal in 2006. Another deal followed in 2008, and this time Ranbaxy was acquired by Japan’s Daiichi Sankyo.
Terapia posted EUR106 million revenue almost EUR22 million net profit last year, which makes it the leading pharmaceuticals producer in Romania.
The Ranbaxy group posted $2.3 billion revenue last year and has 16 production facilities in eight countries. The plant in Cluj is its third most important and the largest in Europe (it has another plant in Ireland it bought in mid nineties but much smaller than the one in Cluj).
“Romania is strategically placed between East and West, between developed and emerging countries.”
Estimates show that two thirds of the expansion of the global pharmaceutical market will happen on emerging markets. Developed countries are experiencing such pressure on healthcare costs that they will have to focus on generic drugs, which is precisely Ranbaxy’s business and Ranbaxy is well positioned in Romania to take advantage of that, Arun Sawhney said.
Terapia’s exports are close to 100 million lei (EUR22.5 million) and its best selling product abroad is Faringosept. It also exports prescription drugs, but the company would not specify what those products were.
“We will make new investments. We have the capacity to expand the business from the current scale (…) If we decide to implement such plans, they will begin in 2014 (…)”
Asked whether Terapia exported drugs to the US, Arun Sawhney said it did not but some parts of the company received an inspection of the US Food and Drug Administration and would consider the opportunity in the future.
Ranbaxy is the first multinational in the pharmaceutical business announcing plans to invest in the development of local capacity. GlaxoSmithKline (GSK), which owns the Europharm plant in Brasov, has recently announced it would sell it and would close it if unsuccessful.
Arun Sawhney says he had no idea GSK is planning to sell and will focus on the investments Ranbaxy already has going in Romania. “I’m not saying we won’t look at good opportunities,” he added.
Asked if something similar might happen to Terapia (i.e. Ranbaxy decides to sell or close the plant), Ranbaxy’s CEO said, “Never.”
Ranbaxy is ninth largest pharmaceutical company in Romania, with a 3.7% market share according to market research company Cegedim Romania. The local pharmaceutical market stands at more than EUR2.6 billion and its leading players are Sanofi, Roche, Novartis, Servier, Pfizer and GSK.
(English version by Loredana Fratila-Cristescu)